WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317110
CAS#: 163706-36-3 (sodium)
Description: Cangrelor is a P2Y12 inhibitor, and was approved in June 2015 as an antiplatelet drug for intravenous application. Cangrelor is a high-affinity, reversible inhibitor of P2Y12 receptors that causes almost complete inhibition of ADP-induced platelet aggregate. It is a modified ATP derivative stable to enzymatic degradation. It does not require metabolic conversion to an active metabolite. This allows cangrelor’s immediate effect after infusion, and the therapeutic effects can be maintained with continuous infusion.
MedKoo Cat#: 317110
Name: Cangrelor sodium
CAS#: 163706-36-3 (sodium)
Chemical Formula: C17H21Cl2F3N5Na4O12P3S2
Exact Mass: 774.94831
Molecular Weight: 864.27
Elemental Analysis: C, 23.63; H, 2.45; Cl, 8.20; F, 6.59; N, 8.10; Na, 10.64; O, 22.21; P, 10.75; S, 7.42
Related CAS #: 163706-06-7 (free acid) 163706-36-3 (sodium)
Synonym: AR-C69931MX; AR C69931MX; ARC69931MX; AR-C69931; AR C69931; ARC69931; Cangrelor; Cangrelor tetrasodium salt
IUPAC/Chemical Name: (dichloro((((((2R,3S,4R,5R)-3,4-dihydroxy-5-(6-((2-(methylthio)ethyl)amino)-2-((3,3,3-trifluoropropyl)thio)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)methyl)phosphonic acid, tetrasodium salt
InChi Key: COWWROCHWNGJHQ-OPKBHZIBSA-J
InChi Code: InChI=1S/C17H25Cl2F3N5O12P3S2.4Na/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32;;;;/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32);;;;/q;4*+1/p-4/t8-,10-,11-,14-;;;;/m1..../s1
SMILES Code: O=P(C(Cl)(P(O[Na])(O[Na])=O)Cl)(OP(OC[C@H]1O[C@@H](N2C=NC3=C(NCCSC)N=C(SCCC(F)(F)F)N=C23)[C@H](O)[C@@H]1O)(O[Na])=O)O[Na]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 864.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Bhattad VB, Gaddam S, Lassiter MA, Jagadish PS, Ardeshna D, Cave B, Khouzam RN. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Ann Transl Med. 2019 Sep;7(17):408. doi: 10.21037/atm.2019.07.64. Review. PubMed PMID: 31660307; PubMed Central PMCID: PMC6787394.
2: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548439/ PubMed PMID: 31643758.
3: Loffi M, Galeazzi G, Di Tano G, Pedroni P, Passamonti E. Who was the culprit? Non-ST-elevation acute coronary syndrome treated with percutaneous coronary intervention and cangrelor infusion. Minerva Cardioangiol. 2019 Oct;67(5):439-442. doi: 10.23736/S0026-4725.19.04916-8. PubMed PMID: 31637900.
4: Gernhofer YK, Banks DA, Golts E, Pretorius V. Novel Use of Cangrelor With Heparin During Cardiopulmonary Bypass in Patients With Heparin-Induced Thrombocytopenia Who Require Cardiovascular Surgery: A Case Series. Semin Thorac Cardiovasc Surg. 2019 Oct 11. pii: S1043-0679(19)30318-1. doi: 10.1053/j.semtcvs.2019.10.002. [Epub ahead of print] PubMed PMID: 31610233.
5: Ciolek AM, Ma K, Garan AR, Eisenberger AB, Jennings DL. Use of cangrelor during venoarterial extracorporeal membrane oxygenation following percutaneous coronary intervention. Artif Organs. 2019 Oct 10. doi: 10.1111/aor.13563. [Epub ahead of print] PubMed PMID: 31602658.
6: Cereda AF, Morici N, Aseni P, Chiara O. Cangrelor bridging strategy for liver damage after mechanical chest compression. Anatol J Cardiol. 2019 Sep;22(4):E8-E9. doi: 10.14744/AnatolJCardiol.2019.78546. PubMed PMID: 31584440.
7: Tanaka KA, Henderson R, Williams B. Heparin-Induced Thrombocytopenia and Cardiac Surgery: Can We Do It All With Cangrelor? A A Pract. 2019 Nov 1;13(9):366. doi: 10.1213/XAA.0000000000001094. PubMed PMID: 31567127; PubMed Central PMCID: PMC6818991.
8: Scala E, Pitta-Gros B, Pantet O, Iafrate M, Kirsch M, Marcucci C, Alberio L. Cardiac Surgery Successfully Managed With Cangrelor in a Patient With Persistent Anti-PF4/Heparin Antibodies 8 Years After Heparin-Induced Thrombocytopenia. J Cardiothorac Vasc Anesth. 2019 Nov;33(11):3073-3077. doi: 10.1053/j.jvca.2019.06.044. Epub 2019 Jul 6. PubMed PMID: 31420311.
9: Abdennour L, Sourour N, Drir M, Premat K, Shotar E, Taylor G, Godier A, Mathout J, Lenck S, Bernard R, Carpentier A, Degos V, Clarençon F. Preliminary Experience with Cangrelor for Endovascular Treatment of Challenging Intracranial Aneurysms. Clin Neuroradiol. 2019 Jul 15. doi: 10.1007/s00062-019-00811-2. [Epub ahead of print] PubMed PMID: 31309241.
10: Yong CM, Sundaram V, Abnousi F, Olivier CB, Yang J, Stone GW, Steg PG, Michael Gibson C, Hamm CW, Price MJ, Deliargyris EN, Prats J, White HD, Harrington RA, Bhatt DL, Mahaffey KW; CHAMPION PHOENIX Investigators. The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. Clin Cardiol. 2019 Jun 29. doi: 10.1002/clc.23221. [Epub ahead of print] PubMed PMID: 31254472; PubMed Central PMCID: PMC6727881.
11: Ubaid S, Ford TJ, Berry C, Murray HM, Wrigley B, Khan N, Thomas MR, Armesilla AL, Townend JN, Khogali SS, Munir S, Martins J, Hothi SS, McAlindon EJ, Cotton JM. Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial. Thromb Haemost. 2019 Jul;119(7):1171-1181. doi: 10.1055/s-0039-1688789. Epub 2019 May 26. PubMed PMID: 31129911.
12: Chen Y, Bernardo NL, Waksman R. Cangrelor for the Rescue of Intra-Procedural Stent Thrombosis in Percutaneous Coronary Intervention. Cardiovasc Revasc Med. 2019 Jul;20(7):624-625. doi: 10.1016/j.carrev.2019.04.018. Epub 2019 Apr 24. PubMed PMID: 31088721.
13: Morici N, Nava S, Sacco A, Viola G, Oreglia J, Meani P, Oliva F, Ranucci M, Leonardi S, Rossini R. Acute myocardial infarction complicating ischemic stroke: is there room for cangrelor? Platelets. 2019 May 8:1-4. doi: 10.1080/09537104.2019.1609663. [Epub ahead of print] PubMed PMID: 31066332.
14: Godier A, Mesnil M, De Mesmay M, Dagois S, Thion LA, Dupont C, Mazighi M, Devys JM. Bridging antiplatelet therapy with cangrelor in patients with recent intracranial stenting undergoing invasive procedures: a prospective case series. Br J Anaesth. 2019 Jul;123(1):e2-e5. doi: 10.1016/j.bja.2019.03.019. Epub 2019 Apr 19. PubMed PMID: 31010645.
15: Guvvala V, Chidambaram Subramanian V, Anireddy JS. A study on structural characterization of degradation products of cangrelor using LC/QTOF/MS/MS and NMR. J Pharm Biomed Anal. 2019 Jun 5;170:327-334. doi: 10.1016/j.jpba.2019.03.031. Epub 2019 Mar 28. PubMed PMID: 30978606.
16: Erlinge D. Cangrelor for ST-Segment-Elevation Myocardial Infarction. Circulation. 2019 Apr 2;139(14):1671-1673. doi: 10.1161/CIRCULATIONAHA.119.039253. PubMed PMID: 30933619.
17: Lu H, Guan W, Zhou Y, Tang Z, Bao H. Cangrelor or Clopidogrel in Patients with Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials. Diabetes Ther. 2019 Jun;10(3):937-950. doi: 10.1007/s13300-019-0593-7. Epub 2019 Mar 23. PubMed PMID: 30905057; PubMed Central PMCID: PMC6531549.
18: Hu TY, Peeters SM, Nagasawa DT, Kamdar NV, Brook RP, Sun J, Park S, Moreland NC, Cruz D, Macyszyn L, Press MC. Cangrelor Bridging Within 6 Months of a Drug-Eluting Stent in a Patient for Emergency Cervical Spine Surgery: A Case Report. A A Pract. 2019 Jul 15;13(2):69-73. doi: 10.1213/XAA.0000000000000994. PubMed PMID: 30864953.
19: Droppa M, Vaduganathan M, Venkateswaran RV, Singh A, Szumita PM, Roberts RJ, Qamar A, Hack L, Rath D, Gawaz M, Fuernau G, de Waha-Thiele S, Desch S, Schneider S, Ouarrak T, Jaffer FA, Zeymer U, Thiele H, Bhatt DL, Geisler T. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y(12) inhibition from the IABP-SHOCK II trial. Resuscitation. 2019 Apr;137:205-212. doi: 10.1016/j.resuscitation.2019.02.008. Epub 2019 Feb 18. PubMed PMID: 30790690.
20: Hideo-Kajita A, Rogers T, Buchanan K, Iantorno M, Gajanana D, Ozaki Y, Dan K, Kolm P, Brathwaite E, Beyene S, Melaku G, Meirovich Y, Dheendsa A, Garcia-Garcia HM, Torguson R, Waksman R. Effects of Cangrelor as Adjunct Therapy to Percutaneous Coronary Intervention. Am J Cardiol. 2019 Apr 15;123(8):1228-1238. doi: 10.1016/j.amjcard.2019.01.031. Epub 2019 Jan 25. PubMed PMID: 30738570.
